Hoverink Biotechnologies

Hoverink Biotechnologies, Inc. was a Los Angeles-based biopharmaceutical company that specialized in the development of non-opioid therapeutics for chronic pain and oncology-related supportive care. The company's lead candidate, LADAVRU, was a proprietary formulation of dronabinol designed for intravenous or oral delivery to alleviate chronic pain, nausea, and neuropathy in patients with various cancers. Beyond human health, Hoverink pursued veterinary applications through MAXKAFLEN, an antibiotic intended for use in cattle and swine. The company also maintained a distinct business segment focused on the manufacture of transparent body armor and protective clothing for defense and law enforcement. Hoverink was previously listed on the NASDAQ under the symbol HVBH but is currently reported as out of business. Its operations were primarily centered in California, led by executives Cyrus Sajna and Debbie Mae Carter.